mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.

Item

http://www.wikidata.org/entity/Q41754200

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

mTOR-inhibitor treatment of me ...... 3D to evaluate tumor response.

@en

type

Item

label

mTOR-inhibitor treatment of me ...... 3D to evaluate tumor response.

@en

prefLabel

mTOR-inhibitor treatment of me ...... 3D to evaluate tumor response.

@en

P1476

mTOR-inhibitor treatment of me ...... 3D to evaluate tumor response.

@en

P2093

B Escudier

http://www.w3.org/2001/XMLSchema#string

K Slimane

http://www.w3.org/2001/XMLSchema#string

M Wagner

http://www.w3.org/2001/XMLSchema#string

R Elaidi

http://www.w3.org/2001/XMLSchema#string

R Renard Penna

http://www.w3.org/2001/XMLSchema#string

S Oudard

http://www.w3.org/2001/XMLSchema#string

S Raslan

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

P2888

s00330-015-3828-7

P304

278-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00330-015-3828-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Lucidarme

Michele Lamuraglia

P577

2015-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25953002

http://www.w3.org/2001/XMLSchema#string